Tirzepatide Side Effects: 56% Gut Symptoms, One in 15 Stop

A 64-year-old woman died of fulminant necrotizing pancreatitis soon after starting tirzepatide, and the FDA’s own postmarketing list already carried the sentence that describes her death: hemorrhagic and necrotizing pancreatitis, sometimes resulting in death. Sellers of the drug quote the friendlier number from the same document, the 56%, and skip the page it came from. Type tirzepatide side effects into a search bar and that is roughly the version you get. Both figures belong to the same drug, and a person deciding whether to take a fourth injection deserves both of them.

Here is the short answer first, because it is the sentence someone will lift. Tirzepatide’s two US labels put gastrointestinal side effects at 56% of patients in the weight-loss trials against 30% on placebo, nausea between 25% and 29%, and discontinuation because of side effects at up to 6.7%, which is one in fifteen at the top dose. Pancreatic injury was confirmed by adjudication in 0.2% of those patients, and the postmarketing section names pancreatitis that kills. Each figure below comes from the label, the registry, the letter, or the journal that published it.

Zepbound and Mounjaro – one molecule, two side effect tables

Tirzepatide ships under two names. Zepbound is the weight-reduction label and Mounjaro is the type 2 diabetes label. Both were revised in August 2026 and both are readable in full from the DailyMed record that the National Library of Medicine publishes.

The Zepbound label pools two placebo-controlled weight-reduction trials, 2,519 adults treated for up to 72 weeks. In that table, nausea runs 8% on placebo and 25%, 29% and 28% on 5 mg, 10 mg and 15 mg. Diarrhea runs 8% against 19%, 21% and 23%. Vomiting runs 2% against 8%, 11% and 13%. Constipation runs 5% against 17%, 14% and 11%. Abdominal pain runs 5% against 9%, 9% and 10%.

The Mounjaro label draws its table from two placebo-controlled diabetes trials with 718 adults. Nausea runs 4% on placebo and 12%, 15% and 18% on the three doses. Diarrhea runs 9% against 12%, 13% and 17%. Decreased appetite runs 1% against 5%, 10% and 11%. Vomiting runs 2% against 5%, 5% and 9%.

Same molecule. Nausea of 29% in one table and 18% in the other, and both of them true, because the populations and the doses differ. The label says the quiet part out loud in its own opening line: adverse reaction rates from clinical trials of one drug cannot be compared directly to rates in trials of another drug. A clinic quoting 18% to a weight-loss patient is quoting a diabetic trial, and the arithmetic is not in the patient’s favour.

The discontinuation rates – who quits, and in which month

The Zepbound pool records who walked away. Permanent discontinuation because of an adverse reaction ran 4.8% at 5 mg, 6.3% at 10 mg and 6.7% at 15 mg, against 3.4% on placebo. Gastrointestinal events alone drove 1.9%, 3.3% and 4.3% of those stops, against 0.5% on placebo. Across all three doses, 56% of treated patients reported a gastrointestinal reaction against 30% on placebo, and the label notes that most of the nausea, vomiting and diarrhea landed during dose escalation and eased with time.

The label also states where the quitting happens: the majority of patients who stopped because of an adverse reaction did so during the first few months, with gastrointestinal events as the reason. The first month of a tirzepatide schedule is a sorting process, and the manufacturer printed that in advance.

Pancreatitis – the tirzepatide side effect the clinics leave out

Adjudicated acute pancreatitis appeared in 0.2% of the weight-reduction pool, which works out to 0.14 cases per 100 patient-years against 0.15 on placebo. In the trials of tirzepatide for another indication, 14 events in 13 treated patients were confirmed, or 0.23 per 100 patient-years against 0.11 in the comparator group. In the two obstructive sleep apnea studies, the exposure-adjusted rate was 0.84 per 100 patient-years on Zepbound and zero on placebo.

Those are small numbers, and small numbers are exactly where a directory stops being useful. So here is what a 0.2% looks like when it lands on one person. Grennan, Borg and Meneley published a case report on April 25, 2025 in JCEM Case Reports describing a 64-year-old woman, described as low risk, who developed fulminant necrotizing pancreatitis after starting tirzepatide and died. The authors state that no previous report had described fulminant necrotizing pancreatitis with a fatal outcome on this drug, and they argue that necrotizing pancreatitis belongs in a boxed warning. That last part is the authors’ recommendation, not an FDA action, and the report does not say whether her product came from a pharmacy counter or a vial sold online.

A second case, published in Cureus on July 5, 2025, describes a 32-year-old woman five weeks into tirzepatide for weight loss. She had taken four doses at 2.5 mg and one at 5 mg. Her lipase came back at 11,645 U/L, with imaging showing acute interstitial oedematous pancreatitis. Gallstones were present as an alternative explanation, the authors call the drug link probable rather than proven, and she recovered after the drug stopped. The label’s advice at that point is its own: discontinue if pancreatitis is suspected. A rate printed as 0.2% is not a promise about the person holding the pen.

Lipase and amylase – the tirzepatide side effects that show up on a blood test

The Zepbound label reports mean increases from baseline in serum pancreatic amylase of 20% to 25% and serum lipase of 28% to 35%, against 2.1% and 5.8% on placebo. It then adds the honest caveat that the clinical significance of those elevations is unknown when there are no other signs or symptoms of pancreatitis.

This is the lab result that sends people to a search bar at midnight, and the label gives the calmest available reading. A modestly raised lipase on this drug is an expected state. The case above was a different situation: severe abdominal pain, a lipase more than twenty times the usual upper limit, and imaging to match. Doctors read the pattern, not the single number.

Hair loss and dysesthesia – the tirzepatide side effects patients notice first

Hair loss shows up in the Zepbound table at 5%, 4% and 5% across doses against 1% on placebo, and the label breaks it down by sex: 7.1% of women against 0.5% of men, against 1.3% and 0% on placebo. The label attributes the hair loss to weight reduction itself, and notes that no treated patient in the pool stopped treatment over it.

Dysesthesia is the awkward one. It means an unpleasant skin sensation, tingling or burning or a light touch that hurts. Zepbound lists it in 0.2%, 0.2% and 0.4% of patients across the three doses against 0.1% on placebo. The Mounjaro label, drawing on a cardiovascular outcomes trial of 6,647 adults with diabetes and established cardiovascular disease, lists dysesthesia at 0.7%. Retatrutide made the word famous in 2026. Tirzepatide carried a smaller version of the same signal in a table most patients skip.

Aspiration, kidneys and the rest of the page

Two labels, and the shorter list is the one patients get told last. The Zepbound label carries a warning about pulmonary aspiration during general anesthesia or deep sedation, and its postmarketing section records aspiration, plus acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis.

The oral-medication interaction is the newest documented surprise. A case report published in Cureus on September 29, 2026 describes a 53-year-old man with multiple sclerosis who had taken sustained-release morphine at 180 mg per day for 13 years without incident. Six weeks after starting tirzepatide at 2.5 mg weekly and stepping to 5 mg, he arrived with opioid-induced respiratory failure and needed 12 mg of intranasal naloxone. The authors point at delayed gastric emptying changing how the morphine tablet releases, plus dehydration reducing clearance of the active metabolite. The label’s guidance is narrower than the case: it warns that tirzepatide delays gastric emptying and can affect the absorption of oral medicines, and it lists that interaction without the dramatic ending over one patient.

Smaller entries in the same trials: acute kidney injury in 0.5% of treated patients against 0.2% on placebo, hypotension in 1.6% against 0.1%, and 2.2% among patients already on blood-pressure medication, cholecystitis in 0.7% against 0.2%, immediate hypersensitivity reactions within a day of a dose in 2.1% against 0.4%, and a mean resting heart rate rise of 1 to 3 beats per minute. Hypoglycemia below 54 mg/dL appeared in 4.2% of the diabetes weight-loss trial patients against 1.3% on placebo. The page reads like an inventory of ways a body can dehydrate.

A third case, published December 10, 2025, is the one that belongs next to any vial sold without a prescriber in the loop. A 39-year-old man with no significant medical history escalated his own tirzepatide dose rapidly, then arrived with life-threatening hypoglycemia, electrolyte derangement, pancytopenia and aspiration pneumonia. He needed mechanical ventilation, renal replacement therapy and a tracheostomy. The dose step is a clinical decision, and doing arithmetic on your own vial is how a schedule becomes an intensive care bed.

The compounded vials – what the FDA found when it opened the paperwork

Anyone injecting a compounded product is not measuring the drug in either table. The FDA’s page on unapproved GLP-1 drugs, whose content is dated October 1, 2026, states that as of May 31, 2026 it had received more than 730 reports of adverse events associated with compounded tirzepatide, and 990 for compounded semaglutide. The same page adds the caveat that matters more than the totals: federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, so the counts understate what happens.

The agency also describes the pattern behind some of those reports. It has received reports of patients prescribed compounded tirzepatide at doses beyond what the approved label contains, meaning a larger single dose, more frequent doses, or faster escalation, and it says some of those events were serious enough that patients sought medical attention. It has also identified fraudulent compounded tirzepatide where the label named a pharmacy that did not make the product.

The paperwork failures are the part with numbers attached. The FDA wrote to Boothwyn Pharmacy on January 16, 2026 after an inspection that ran from May 12 to June 9, 2025. Investigators found a Tirzepatide 17 mg/mL vial that failed sterility testing, and Tirzepatide 10 mg/mL lots that were subpotent at 86.779% and 89.13% of the labeled strength. The company recalled out-of-specification products on July 9, 2025 and stopped making sterile GLP-1 products.

Marketers get letters of their own. MEDVi received a warning letter on February 20, 2026, based on a website review in December 2025, for claims that its compounded products were the “same active ingredient as Mounjaro” and “same active ingredient as Zepbound.” OrderlyMeds received one on June 8, 2026 after a March 2026 review of claims that it was an FDA-licensed pharmacy. Compounding facilities are not FDA-approved or FDA-licensed entities, and the FDA treats that sentence as misbranding. A vial that came in at 86.779% of its label explains a patient whose weight loss stalled at week nine, and explains nothing about why they feel sick anyway.

How to check a tirzepatide prescription before a fourth dose

• Get the name of the pharmacy that prepared the product in writing, on the label. A label carrying the marketer’s logo tells you nothing about who compounded it.
• Ask what the product contains in milligrams per millilitre, and match it to the approved Zepbound strengths, which are single-dose pens. Compounded vials and approved pens are not interchangeable formats.
• Read the interaction list before any oral medicine with a narrow window, especially sustained-release opioids, and before any surgery under sedation.
• Take the FDA’s own advice on multiple-dose vials: use within 28 days of the first puncture and discard what remains, even if liquid is left.
• Treat “same active ingredient as Zepbound” as a settled legal question. The FDA has already called that claim false or misleading.
• For a clinic, check the prescriber’s licence record. Our step-by-step NPI check takes about four minutes.
• Report a bad reaction to the FDA’s MedWatch program, whether the product came from a pharmacy or a website.

One comparison the labels cannot make is compounded against approved, because no trial has randomized patients to an approved pen against a compounded vial and published the event rates. That study does not exist, which means any confident comparison between the two is a marketing position rather than a finding. Two limits belong on this page with it: the case reports above describe temporal associations that the authors grade as probable, not proven, and the trial percentages describe fixed dose steps under trial supervision, not a vial measured with a syringe at home.

Frequently asked questions

How common are tirzepatide side effects?

Gastrointestinal reactions were reported by 56% of patients in the weight-reduction trials against 30% on placebo. Nausea ran 25% to 29% across doses, diarrhea 19% to 23%, constipation 11% to 17%, and vomiting 8% to 13%.

Do tirzepatide side effects go away?

The label says most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time, and that the majority of people who stopped because of side effects did so in the first few months. Some events, including pancreatitis and aspiration, are not in the fade-with-time category.

Can tirzepatide cause pancreatitis?

Adjudicated acute pancreatitis was confirmed in 0.2% of patients in the weight-reduction pool, and the FDA postmarketing list for tirzepatide names hemorrhagic and necrotizing pancreatitis, sometimes resulting in death. The label’s instruction when pancreatitis is suspected is to discontinue the drug.

Does tirzepatide cause hair loss?

The label lists hair loss in 5%, 4% and 5% of treated patients across the three Zepbound doses against 1% on placebo, and 7.1% of women against 0.5% of men. The label ties it to weight reduction, and no patients in the pool stopped treatment over it.

What is dysesthesia on tirzepatide?

An unpleasant skin sensation such as tingling, burning or painful light touch. Zepbound lists it in 0.2% to 0.4% of patients, and the Mounjaro label reports 0.7% in a 6,647-patient cardiovascular outcomes trial.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

The FDA has told at least one seller that the claim is false or misleading, because compounded drug products are not FDA-approved. A compounded option is a different regulatory product, and no head-to-head trial of compounded against approved tirzepatide has published side effect rates.

What should I do about severe stomach pain on tirzepatide?

The label instructs patients with suspected pancreatitis to stop the drug and get medical attention, and the case reports above all began with severe, persistent upper abdominal pain. Nothing on this page is a dosing instruction, and no article should replace the clinician who prescribed it.

Two disclosures belong on the record. The percentages on this page come from trials that ran under a manufacturer’s quality controls with fixed, supervised dose steps, and a compounded vial with the same molecule on its label shares very little of that. The case reports describe associations that their authors grade as probable, which is the strongest word the format allows.

Sources: FDA, concerns with unapproved GLP-1 drugs used for weight loss, Zepbound label, DailyMed, Mounjaro label, DailyMed, FDA warning letter 717525 to Boothwyn Pharmacy, January 16, 2026, FDA warning letter 721455 to MEDVi, February 20, 2026, FDA warning letter 728291 to OrderlyMeds, June 8, 2026, Grennan et al., JCEM Case Reports, April 25, 2025, Sumaruth et al., Cureus, July 5, 2025, Sharafeldin et al., Cureus, December 10, 2025, Mataraarachchi et al., Cureus, September 29, 2026, ClinicalTrials.gov, Zepbound weight-reduction study NCT04184622.

For the semaglutide side effect numbers, including what changed when the FDA cleared the higher 7.2 mg dose, read our Wegovy side effects breakdown.